Tiburio is developing TBR-065, a novel, potent dopamine-somatostatin agonist, for the treatment of rare neuroendocrine diseases.
Tiburio is also developing a second compound, TBR-065, for the treatment of rare neuroendocrine disorders. TBR-065 is a novel, potent dopamine-somatostatin agonist from the same family as TBR-760 and has been demonstrated to be safe and well-tolerated in clinical studies. Its unique properties make it the ideal candidate to treat rare neuroendocrine diseases. The Tiburio team is accumulating additional data to determine the optimal indication for TBR-065.
| Preclinical | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|
|
Preclinical
|
Phase 1
|
Phase 2
|
Phase 3
|